+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effect of forphenicinol, a small molecular immunomodifier, in combination with cyclophosphamide on growth of and immunity to syngeneic murine tumors



Effect of forphenicinol, a small molecular immunomodifier, in combination with cyclophosphamide on growth of and immunity to syngeneic murine tumors



Cancer Treatment Reports 69(3): 285-291



Forphenicinol (FPL) is a low molecular immunomodifier derived from forphenicine, a microbial product found by Umezawa and co-workers. We studied the antitumor effect of FPL, cyclophosphamide (CY), and the combination of the two on several syngeneic murine tumors. The tumors used were mammary carcinoma, L1210 leukemia, B16 melanoma, Lewis lung carcinoma, and glioblastoma. A single ip injection of CY on Day 1 followed by eight consecutive daily oral doses of FPL beginning 6 days after tumor inoculation showed strong cooperation in curing syngeneic mammary carcinoma inoculated intradermally in C3H/HeN mice, most mice being cured of the tumor by the combination therapy and subsequently having acquired strong specific immunity. Treatment with FPL alone (either pre- or post-treatment) also significantly inhibited the growth of the mammary tumor. FPL and CY also showed cooperation in inhibiting the growth of L1210 leukemia transplanted intradermally into CDF1 (BALB/c X DBA/2) mice and markedly prolonged the survival time but FPL treatment alone had no effect. The FPL-CY treatment also affected Lewis lung carcinoma and glioblastoma in syngeneic C57BL/6 mice and produced therapeutic synergism. FPL alone significantly inhibited the growth of B16 melanoma in C57BL/6 mice as well as the syngeneic mammary carcinoma in C3H/HeN mice. These findings suggest that oral administration of FPL in combination with chemotherapeutic agents can be used for treating cancer without causing toxicity, because of the synergistic efficacy of the combination.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 005240035

Download citation: RISBibTeXText

PMID: 3978657


Related references

Effect of forphenicinol a small molecular immunomodifier on growth of a syngeneic guinea pig hepatoma and a study of its mechanisms. Uicc (Union Internationale Contre Le Cancer, International Union Against Cancer) 14th International Cancer Congress, Budapest, Hungary, Aug 21-27, Abstracts, Lectures, Symposia And Free Communications, Vols 1, 2, 3, Late Abstracts, And Register Xvi+479p (Vol 1); Xvi+298p (Vol 2); Xvi+531p (Vol 3); 15p (Late Abstracts); 40p (Register) S Karger Ag: Basel, Switzerland; New York, N Y , Usa; Akademiai Kiado: Budapest, Hungary Paper 659, 1986

Antitumor effect of forphenicinol, a low molecular weight immunomodifier, on murine transplantable tumors and microbial infections. Journal of Antibiotics 35(8): 1049-1054, 1982

Effect of forphenicinol, a low molecular weight immunomodifier, on the growth of and the immune responses to murine lymphoma EL4. Journal of Biological Response Modifiers 6(1): 35-43, 1987

Antitumor effect of forphenicinol, a low molecular weight immunomodifier, in combination with surgery on Meth A fibrosarcoma, Lewis lung carcinoma, and adenocarcinoma 755. Journal of Antibiotics 39(4): 564-568, 1986

Changes in the immunological parameters after a single dose of forphenicinol, a new small molecular immunomodifier. Tohoku Journal of Experimental Medicine 146(4): 419-427, 1985

Therapeutic efficacy of human recombinant interleukin-2 (TGP-3) alone or in combination with cyclophosphamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumors. Cancer Immunology, ImmunoTherapy 30(2): 71-80, 1989

Protective effect of forphenicinol, a low molecular weight immunomodifier, against infection with Pseudomonas aeruginosa in mice and its mechanisms. Journal of Antibiotics 40(4): 547-554, 1987

Modulation of anti tumor immunity and the effect of bacterial endotoxin on the growth of different syngeneic tumors from small inocula in mice. British Journal of Experimental Pathology 67(3): 371-382, 1986

Combination therapy with cyclophosphamide and OK-432 augments immunity against murine bladder tumors in mice. Journal of Urology 151(5 SUPPL ): 517A, 1994

Efficacy of BCG presensitization in combination with cyclophosphamide (CY) on murine tumor growth and immunity. Cancer Immunology, ImmunoTherapy 10(1): 57-59, 1980

Effects of cyclophosphamide on immunity against chemically-induced syngeneic murine sarcomas. International Journal of Cancer 13(4): 572-578, 1974

Effect of preliminary administration of cyclophosphamide and pretransplantation irradiation on the growth of syngeneic tumors in mice. Biulleten' Eksperimental'noi Biologii i Meditsiny 95(1): 84-86, 1983

Monoclonal Antibodies to high molecular weight kininogen inhibit growth and neovascularization in murine syngeneic tumors. FASEB Journal 18(4-5): Abst 276 4, 2004

The effect of malaria on the growth of 2 syngeneic transplantable murine tumors. Annals of Tropical Medicine & Parasitology 75(6): 597-606, 1981

The effect of Listeria factor Ei, BCG vaccine and a combination of both on the growth of experimental syngeneic tumors in inbred mice. Sbornik Lekarsky 91(8-9): 230-237, 1989